Sruti Rayaprolu

Sruti Rayaprolu, PhD

Associate Scientist

Department: MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone: (352) 273-9554
Business Email: sruti.rayaprolu@ufl.edu

About Sruti Rayaprolu

In 2018, Sruti Rayaprolu received her PhD in Biomedical Sciences, focused in Neuroscience, at the University of Florida COM. Her graduate work aimed at developing and characterizing animal models of Atypical Parkinson’s disease and ALS. Following this, she pursued a postdoctoral fellowship at Emory University where she investigated the cellular mechanisms of Alzheimer’s disease by isolating specific cell-types (glia, endothelial cells, oligodendrocytes) from human and mouse brain and performing mass spectrometry-based proteomics. She also developed a novel mouse model (Rosa-TurboID) that can be used to capture a snapshot of the cellular proteome of a specific brain cell type while retaining their native state. Using this model, she has successfully defined the proteome of excitatory neurons and astrocytes within the mouse brain. Subsequently, Sruti transitioned to the biotechnology sector where she led the design and execution of pivotal experiments to assess the feasibility, efficacy, and safety of AAV gene therapies in preclinical models of inherited retinal diseases. Sruti’s hobbies include raising chickens, spending time with her two kids and husband, learning how to garden, and watching The Sopranos.

Additional Positions:
Director, CTRND Proteomics and Bioinformatics Initiatives
2024 – Current ·
1FL-ADRC, Biomarker Core Co-Investigator
2024 – Current ·

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-5212-3745

Areas of Interest
  • Alzheimer’s Disease
  • Biomarkers
  • Brain metabolism
  • Cell type-specific proteomics
  • Lysosomal Storage Diseases
  • Mass Spectrometry
  • Neuronal Vulnerability
  • Parkinson’s disease
  • Proximity Labeling

Publications

2023
APOE expression and secretion are modulated by mitochondrial dysfunction.
eLife. 12 [DOI] 10.7554/eLife.85779. [PMID] 37171075.
2023
Cellular Proteomic Profiling Using Proximity Labeling by TurboID-NES in Microglial and Neuronal Cell Lines.
Molecular & cellular proteomics : MCP. 22(6) [DOI] 10.1016/j.mcpro.2023.100546. [PMID] 37061046.
2023
Identification of State-Specific Proteomic and Transcriptomic Signatures of Microglia-Derived Extracellular Vesicles.
Molecular & cellular proteomics : MCP. 22(12) [DOI] 10.1016/j.mcpro.2023.100678. [PMID] 37952696.
2022
Biophysical Kv3 channel alterations dampen excitability of cortical PV interneurons and contribute to network hyperexcitability in early Alzheimer’s.
eLife. 11 [DOI] 10.7554/eLife.75316. [PMID] 35727131.
2022
Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain.
Nature communications. 13(1) [DOI] 10.1038/s41467-022-30623-x. [PMID] 35614064.
2022
Convergent cerebrospinal fluid proteomes and metabolic ontologies in humans and animal models of Rett syndrome.
iScience. 25(9) [DOI] 10.1016/j.isci.2022.104966. [PMID] 36060065.
2021
Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 46(1):98-115 [DOI] 10.1038/s41386-020-00840-3. [PMID] 32898852.
2021
Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer’s disease.
Proceedings of the National Academy of Sciences of the United States of America. 118(11) [DOI] 10.1073/pnas.2013545118. [PMID] 33649184.
2020
Flow Cytometry Approach to Characterize Phagocytic Properties of Acutely-Isolated Adult Microglia and Brain Macrophages In Vitro.
Journal of visualized experiments : JoVE. (160) [DOI] 10.3791/61467. [PMID] 32658196.
2020
Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease.
Molecular neurodegeneration. 15(1) [DOI] 10.1186/s13024-020-00377-5. [PMID] 32381088.
2018
Analysis of spinal and muscle pathology in transgenic mice overexpressing wild-type and ALS-linked mutant MATR3.
Acta neuropathologica communications. 6(1) [DOI] 10.1186/s40478-018-0631-0. [PMID] 30563574.
2018
Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis.
Molecular and cellular neurosciences. 92:17-26 [DOI] 10.1016/j.mcn.2018.05.009. [PMID] 29859891.
2017
A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking.
PloS one. 12(5) [DOI] 10.1371/journal.pone.0173565. [PMID] 28467418.
2017
Retraction Note: Transgenic mice overexpressing the ALS-linked protein Matrin 3 develop a profound muscle phenotype.
Acta neuropathologica communications. 5(1) [DOI] 10.1186/s40478-017-0502-0. [PMID] 29237481.
2016
Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms.
Parkinsonism & related disorders. 22:102-5 [DOI] 10.1016/j.parkreldis.2015.11.016. [PMID] 26627941.
2016
Heterogeneity of Matrin 3 in the developing and aging murine central nervous system.
The Journal of comparative neurology. 524(14):2740-52 [DOI] 10.1002/cne.23986. [PMID] 26878116.
2016
Transgenic mice overexpressing the ALS-linked protein Matrin 3 develop a profound muscle phenotype.
Acta neuropathologica communications. 4(1) [DOI] 10.1186/s40478-016-0393-5. [PMID] 27863507.
2016
TREM2 p.R47H substitution is not associated with dementia with Lewy bodies.
Neurology. Genetics. 2(4) [DOI] 10.1212/NXG.0000000000000085. [PMID] 27458607.
2015
Low density lipoprotein receptor related protein 1 and 6 gene variants and ischaemic stroke risk.
European journal of neurology. 22(8):1235-41 [DOI] 10.1111/ene.12735. [PMID] 26031789.
2015
Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies.
Neurology. 85(19):1680-6 [DOI] 10.1212/WNL.0000000000001946. [PMID] 26333800.
2015
VPS35 and DNAJC13 disease-causing variants in essential tremor.
European journal of human genetics : EJHG. 23(6):887-8 [DOI] 10.1038/ejhg.2014.164. [PMID] 25118025.
2014
Analysis of COQ2 gene in multiple system atrophy.
Molecular neurodegeneration. 9 [DOI] 10.1186/1750-1326-9-44. [PMID] 25373618.
2014
Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data.
BMJ (Clinical research ed.). 349 [DOI] 10.1136/bmj.g4164. [PMID] 25011450.
2014
Frequency of APOE, MTHFR and ACE polymorphisms in the Zambian population.
BMC research notes. 7 [DOI] 10.1186/1756-0500-7-194. [PMID] 24679048.
2014
Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson’s disease.
Neurobiology of aging. 35(8):1958.e1-2 [DOI] 10.1016/j.neurobiolaging.2014.03.004. [PMID] 24684791.
2014
Investigating FUS variation in Parkinson’s disease.
Parkinsonism & related disorders. 20 Suppl 1(0 1):S147-9 [DOI] 10.1016/S1353-8020(13)70035-X. [PMID] 24262168.
2014
LRRK2 exonic variants and risk of multiple system atrophy.
Neurology. 83(24):2256-61 [DOI] 10.1212/WNL.0000000000001078. [PMID] 25378673.
2014
SLC1A2 rs3794087 does not associate with essential tremor.
Neurobiology of aging. 35(4):935.e9-10 [DOI] 10.1016/j.neurobiolaging.2013.09.022. [PMID] 24139280.
2013
Analysis of the C9orf72 repeat in Parkinson’s disease, essential tremor and restless legs syndrome.
Parkinsonism & related disorders. 19(2):198-201 [DOI] 10.1016/j.parkreldis.2012.09.013. [PMID] 23084342.
2013
Association of the APOE, MTHFR and ACE Genes Polymorphisms and Stroke in Zambian Patients.
Neurology international. 5(4) [DOI] 10.4081/ni.2013.e20. [PMID] 24416484.
2013
Genetic variants associated with myocardial infarction in the PSMA6 gene and Chr9p21 are also associated with ischaemic stroke.
European journal of neurology. 20(2):300-8 [DOI] 10.1111/j.1468-1331.2012.03846.x. [PMID] 22882272.
2013
GWAS risk factors in Parkinson’s disease: LRRK2 coding variation and genetic interaction with PARK16.
American journal of neurodegenerative disease. 2(4):287-99 [PMID] 24319646.
2013
Investigating the role of FUS exonic variants in essential tremor.
Parkinsonism & related disorders. 19(8):755-7 [DOI] 10.1016/j.parkreldis.2013.03.005. [PMID] 23601511.
2013
NOTCH3 variants and risk of ischemic stroke.
PloS one. 8(9) [DOI] 10.1371/journal.pone.0075035. [PMID] 24086431.
2013
TARDBP mutations in Parkinson’s disease.
Parkinsonism & related disorders. 19(3):312-5 [DOI] 10.1016/j.parkreldis.2012.11.003. [PMID] 23231971.
2013
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease.
Molecular neurodegeneration. 8 [DOI] 10.1186/1750-1326-8-19. [PMID] 23800361.
2012
A novel de novo pathogenic mutation in the CACNA1A gene.
Movement disorders : official journal of the Movement Disorder Society. 27(12):1578-9 [DOI] 10.1002/mds.25198. [PMID] 23038654.
2012
Angiogenin variation and Parkinson disease.
Annals of neurology. 71(5):725-7; author reply 727 [DOI] 10.1002/ana.23586. [PMID] 22522484.
2012
Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype.
Neurobiology of aging. 33(12):2950.e5-7 [DOI] 10.1016/j.neurobiolaging.2012.07.005. [PMID] 22840558.

Grants

Jun 2024 ACTIVE
Quantification of the neurocognitive, brain, and blood markers of dementia in middle-aged autistic adults
Role: Project Manager
Funding: NATL INST OF HLTH NIA

Contact Details

Phones:
Business:
(352) 273-9554
Emails:
Addresses:
Business Mailing:
PO BOX 100236
GAINESVILLE FL 32610
Business Street:
1275 CENTER DR J418
BIOMEDICAL SCIENCES BLDG
GAINESVILLE FL 32610